Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -140,055 | -107,221 | -71,965 | -43,311 | 1,687,572 |
| Depreciation Amortization | 2,483 | 1,919 | 1,336 | 675 | 2,285 |
| Accounts receivable | 200 | 246 | 119 | 183 | -185 |
| Accounts payable and accrued liabilities | -3,301 | -2,472 | -953 | -353 | 17,903 |
| Other Working Capital | -7,614 | -5,899 | -2,476 | 3,324 | 52,051 |
| Other Operating Activity | 18,493 | 13,755 | 8,091 | 3,587 | -1,954,035 |
| Operating Cash Flow | $-129,794 | $-99,672 | $-65,848 | $-35,895 | $-194,409 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -28 | -28 | -21 | -21 | -2,597 |
| Investing Cash Flow | $-28 | $-28 | $-21 | $-21 | $-2,597 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 99,965 | 99,965 | 99,965 | 99,965 | N/A |
| Debt Repayment | -125 | -125 | -125 | -125 | N/A |
| Common Stock Issued | 1,606 | 352 | 0 | 0 | 71,678 |
| Financing Cash Flow | $101,446 | $100,192 | $99,840 | $99,840 | $71,678 |
| Beginning Cash Position | 152,596 | 152,596 | 152,596 | 152,596 | 277,924 |
| End Cash Position | 124,220 | 153,088 | 186,567 | 216,520 | 152,596 |
| Net Cash Flow | $-28,376 | $492 | $33,971 | $63,924 | $-125,328 |
| Free Cash Flow | |||||
| Operating Cash Flow | -129,794 | -99,672 | -65,848 | -35,895 | -194,409 |
| Capital Expenditure | -31 | -31 | -21 | -21 | -2,597 |
| Free Cash Flow | -129,825 | -99,703 | -65,869 | -35,916 | -197,006 |